Suspension of trading
Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 8.19B 7.09B 6.62B 6.07B 11.42B 780B 11.6B 77.63B 30.47B 391B 30.76B 30.09B 1,292B | P/E 2022 |
-13.6x | P/E 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 7.5B 6.48B 6.06B 5.55B 10.45B 713B 10.61B 71.04B 27.88B 358B 28.15B 27.53B 1,182B | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 30/04/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 19/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 19/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 01/08/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 01/08/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +106.62% | 8.19B | |
| +8.49% | +20.55% | +70.77% | +110.32% | 68.12B | |
| +1.25% | +2.44% | +34.27% | +70.43% | 55.18B | |
| -1.09% | +32.96% | +19.67% | +494.56% | 28.63B | |
| +10.83% | +18.38% | +56.20% | +6.03% | 23.99B | |
| +2.72% | +3.41% | -16.11% | -7.96% | 23.53B | |
| +6.50% | +7.56% | +44.65% | -21.73% | 18.45B | |
| +6.20% | +11.51% | +33.87% | +693.38% | 16.44B | |
| -3.88% | +16.98% | +199.30% | +359.77% | 15.83B | |
| +3.58% | +1.96% | +43.35% | +163.76% | 13.4B | |
| Average | +3.53% | +10.51% | +48.60% | +197.52% | 27.18B | |
| Weighted average by Cap. | +4.25% | +12.70% | +49.16% | +166.61% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -352M -304M -284M -260M -490M -33.45B -498M -3.33B -1.31B -16.77B -1.32B -1.29B -55.43B | -433M -374M -350M -321M -603M -41.19B -613M -4.1B -1.61B -20.65B -1.63B -1.59B -68.26B |
| Net Debt | -523M -453M -423M -388M -729M -49.8B -741M -4.96B -1.95B -24.96B -1.96B -1.92B -82.52B | -695M -602M -562M -515M -969M -66.18B -985M -6.59B -2.59B -33.17B -2.61B -2.55B -110B |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Select your edition
All financial news and data tailored to specific country editions
